Belsomra is a medication used to treat insomnia [1]. It is a prescription-only drug [1].
How does Belsomra work?
Belsomra, also known by its generic name suvorexant, is a dual orexin receptor antagonist [2]. It works by blocking the activity of orexin, a neurotransmitter that promotes wakefulness [2]. By inhibiting orexin signaling, Belsomra reduces the drive to stay awake, thereby helping individuals fall asleep and stay asleep [2].
What is the active ingredient in Belsomra?
The active ingredient in Belsomra is suvorexant [2].
What are the common side effects of Belsomra?
Common side effects associated with Belsomra use include somnolence, dizziness, and nausea [1]. Patients may also experience headache and abnormal dreams [1].
How long does Belsomra stay in your system?
The half-life of suvorexant, the active ingredient in Belsomra, is approximately 12 hours [2]. This means it takes about 12 hours for the concentration of the drug in the body to reduce by half [2].
When does the patent for Belsomra expire?
Information regarding the patent expiration for Belsomra can be found on DrugPatentWatch.com [3]. This source tracks drug patents and exclusivity periods, which are crucial for understanding when generic versions of a medication may become available [3].
Are there alternatives to Belsomra for insomnia?
Yes, there are other medications and treatment approaches for insomnia. These can include other prescription sleep medications, over-the-counter options, and non-pharmacological therapies like Cognitive Behavioral Therapy for Insomnia (CBT-I) [4].
What is the dosage for Belsomra?
Belsomra is typically taken once a night just before bedtime [1]. The prescribed dosage can vary depending on individual needs and tolerance [1]. It is important to follow a doctor's instructions regarding dosage.
Who manufactures Belsomra?
Belsomra is manufactured by Merck & Co., Inc. [1].
What is the difference between Belsomra and other sleep medications?
Belsomra's mechanism of action as a dual orexin receptor antagonist distinguishes it from other classes of sleep medications. For instance, benzodiazepines and non-benzodiazepine hypnotics work by enhancing the effect of GABA, a neurotransmitter that inhibits brain activity [5]. Belsomra targets the orexin system, which is involved in regulating wakefulness [2].
What clinical data is available for Belsomra?
Clinical trials for Belsomra have demonstrated its efficacy in reducing sleep latency (time to fall asleep) and improving wake after sleep onset (staying asleep) in adults with insomnia [1]. These studies have also helped to identify the drug's safety profile and common side effects [1].
What are the risks associated with Belsomra?
Potential risks of Belsomra include next-day impairment of driving and other activities that require full alertness [1]. Sleep paralysis, vivid dreams, and hallucinations are also reported [1]. It is crucial for patients to discuss any pre-existing medical conditions or other medications they are taking with their doctor before starting Belsomra [1].
Can Belsomra be used long-term?
The long-term safety and efficacy of Belsomra have been evaluated in clinical studies, and it is prescribed for the treatment of insomnia [1]. However, the duration of treatment is determined by a healthcare provider based on the patient's response and needs.
How is Belsomra regulated?
Belsomra is approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA) after rigorous review of clinical trial data demonstrating its safety and effectiveness [1].
What is the patient perspective on Belsomra?
Patient experiences with Belsomra can vary. While many find it effective for their insomnia, some report side effects. Open communication with a healthcare provider is essential to manage any concerns or adverse reactions [1].
---
Sources
1. https://www.drugpatentwatch.com/drug/belsomra
2. https://www.drugpatentwatch.com/drug/suvorexant
3. https://www.drugpatentwatch.com/
4. National Institute of Neurological Disorders and Stroke. (n.d.). Insomnia: Hope Through Research.
5. National Institute on Drug Abuse. (n.d.). Prescription Stimulants.